COVID Relief and Cannabis Legalization |
Quarterly Insights from the RAND Drug Policy Research Center | View in browser
|
|
Quarterly insights from the RAND Drug Policy Research Center |
AUG 2020
|
|
|
|
Cannabis legalization is a multifaceted decision with implications for health, safety, and social equity. Whether legalization could fund COVID relief should not be a major focus of these debates. Read more »
|
|
|
Photo by Chinnapong/Getty Images
|
Evidence shows waivered-clinicians who are able to prescribe buprenorphine treat fewer patients than their limit allows. With so much unmet demand for opioid use disorder treatment, this suggests the need for ongoing efforts to address treatment barriers.
Read more »
|
|
|
|
Photo by SDI Productions/Getty Images |
Co-occurring substance use and mental health disorders are common among post-9/11 veterans. But treatment programs typically specialize in one issue or the other. Integrated treatments are more effective and have become more available, but it's critical that veterans have access to facilities that are equipped to treat them.
Read more »
|
|
|
|
Photo by monsitj/Getty Images |
The RAND-USC Schaeffer Opioid Policy Tools and Information Center is hosting a free seminar on September 14, 2020. Topics include: Strengths and limitations of state opioid policy data sources, measuring changes over time, and more.
Read more »
|
|
|
|
Photo by NewGig86/Getty Images
|
The existing literature on naloxone access laws in the United States supports beneficial effects for increased naloxone distribution, but provides inconclusive evidence for reduced fatal opioid overdose.
Read more »
|
|
|
|
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis.
|
|
Privacy statement
|
|
RAND Corporation. 1776 Main Street, Santa Monica, CA 90401-3208. RAND® is a registered trademark.
|
|
|
|
|